Skip to main content
Premium Trial:

Request an Annual Quote

Interleukin Genetics' Q2 Revenues Decline

NEW YORK (GenomeWeb News) – Genetic test maker Interleukin Genetics reported after the close of the market Thursday that its second-quarter revenues fell 57 percent year over year due to lower contract research revenue.

The Waltham, Mass.-based firm generated total revenues of $222,993 for the three-month period ended June 30, down from total revenues of $521,619 for the second quarter of 2008. The company's contract service revenues fell sharply to $119,046 from $402,280, while its genetic testing service revenue increased to $95,309 from $90, 993.

Interleukin's net loss for the quarter was $3.7 million, or $.12 per share, more than double its net loss for Q2 2008 of $1.7 million, or $.05 per share.

Its R&D spending increased to $874,192 from $708,855, and its SG&A expenses climbed to $1.3 million from $1.2 million.

"We further executed on our key strategic objective, which is to grow our genetic testing business, by divesting the Alan James Group and signing a licensing partnership with LABEC Pharma for sales and distribution of our Heart Health product in Spain and Portugal," Interleukin CEO Lewis Bender said in a statement.

Interleukin Genetics finished the quarter with $851,526 in cash and cash equivalents. The firm noted that it also has $4.4 million in cash proceeds received on July 1 from the sale of its Alan James Group subsidiary.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.